The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|September 27, 2011
XDS MasterLab - FOSS NIRSystems, Inc
Content Uniformity Made Easy The FOSS MasterLab is based on XDS Near-Infrared (NIR) technology and provides pharmaceutical manufacturers with a rapid, reliable and non-destructive test method covering the full array of solid dosage forms: layered, coated or cored tablets, capsules, caplets, geltabs and gelcaps. The versatile sampling mechanism of the MasterLab offers an automated and unattended reflectance or transmission analysis of a tray of multiple tablets or vials. Visit FOSS NIRSystems Learn more about the XDS MasterLab Contact Us
Advertisement
Content Uniformity Made Easy
The FOSS MasterLab is based on XDS Near-Infrared (NIR) technology and provides pharmaceutical manufacturers with a rapid, reliable and non-destructive test method covering the full array of solid dosage forms: layered, coated or cored tablets, capsules, caplets, geltabs and gelcaps.
The versatile sampling mechanism of the MasterLab offers an automated and unattended reflectance or transmission analysis of a tray of multiple tablets or vials.
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement